A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

Podobne zapisy

• A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
  od: Gordon, Michael S., i wsp.
  Wydane: (2012)
• A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
  od: Eskens, F A L M, i wsp.
  Wydane: (2008)
• A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia
  od: Kirschbaum, Mark, i wsp.
  Wydane: (2011)
• Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
  od: Awada, A. H., i wsp.
  Wydane: (2012)
• Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
  od: Schnell, David, i wsp.
  Wydane: (2014)